Mariam El-Zein1,2, Farzin Khosrow-Khavar2, Ann N Burchell3,4, Pierre-Paul Tellier5, Shaun Eintracht6, Elizabeth McNamara6, Francois Coutlée7, Eduardo L Franco1,2. 1. Division of Cancer Epidemiology, McGill University, Montréal, Québec, Canada. 2. Gerald Bronfman Department of Oncology, McGill University, Montréal, Québec, Canada. 3. Department of Family and Community Medicine and MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada. 4. Department of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. 5. Department of Family Medicine, McGill University, Montréal, Québec, Canada. 6. Department of Diagnostic Medicine, Jewish General Hospital, Montréal, Québec, Canada. 7. Départements de Clinique de Médecine de Laboratoire et de Médecine, Services de Biologie Moléculaire et d'Infectiologie, Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.
Abstract
BACKGROUND: We assessed the association between serum 25-hydroxyvitamin D levels and genital human papillomavirus (HPV) prevalence, incidence, and clearance among female participants in the HPV Infection and Transmission among Couples through Heterosexual activity (HITCH) Cohort Study. METHODS: We genotyped HPV DNA in vaginal samples and quantified baseline serum 25-hydroxyvitamin D levels using Roche's Linear Array and Total vitamin D assay, respectively. We used logistic and Cox proportional hazards models, respectively, to estimate adjusted odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs). RESULTS: There was no association between vitamin D levels (every 10-ng/mL increase) at baseline and HPV prevalence (OR, 0.88; 95% CI, .73-1.03) or incidence (HR, 0.88; 95% CI, .73-1.06), but we observed a modest negative association with HPV clearance (HR, 0.76; 95% CI, .60-.96). Vitamin D levels <30 ng/mL, compared with those ≥30 ng/mL, were not associated with HPV prevalence (OR, 0.98; 95% CI, .57-1.69) or incidence (HR, .87; 95% CI, .50-1.43), but they were associated with a marginally significant increased clearance (OR, 2.14; 95% CI, .99-4.64). We observed consistent results with restricted cubic spline modeling of vitamin D levels and clinically defined categories. HPV type-specific analyses accounting for multiple HPV infections per participant showed no association between vitamin D levels and all study outcomes. CONCLUSIONS: This study provided no evidence of an association between low vitamin D levels and increased HPV prevalence, acquisition, or clearance.
BACKGROUND: We assessed the association between serum 25-hydroxyvitamin D levels and genital human papillomavirus (HPV) prevalence, incidence, and clearance among female participants in the HPV Infection and Transmission among Couples through Heterosexual activity (HITCH) Cohort Study. METHODS: We genotyped HPV DNA in vaginal samples and quantified baseline serum 25-hydroxyvitamin D levels using Roche's Linear Array and Total vitamin D assay, respectively. We used logistic and Cox proportional hazards models, respectively, to estimate adjusted odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs). RESULTS: There was no association between vitamin D levels (every 10-ng/mL increase) at baseline and HPV prevalence (OR, 0.88; 95% CI, .73-1.03) or incidence (HR, 0.88; 95% CI, .73-1.06), but we observed a modest negative association with HPV clearance (HR, 0.76; 95% CI, .60-.96). Vitamin D levels <30 ng/mL, compared with those ≥30 ng/mL, were not associated with HPV prevalence (OR, 0.98; 95% CI, .57-1.69) or incidence (HR, .87; 95% CI, .50-1.43), but they were associated with a marginally significant increased clearance (OR, 2.14; 95% CI, .99-4.64). We observed consistent results with restricted cubic spline modeling of vitamin D levels and clinically defined categories. HPV type-specific analyses accounting for multiple HPV infections per participant showed no association between vitamin D levels and all study outcomes. CONCLUSIONS: This study provided no evidence of an association between low vitamin D levels and increased HPV prevalence, acquisition, or clearance.
Authors: François Coutlée; Danielle Rouleau; Patrick Petignat; Georges Ghattas; Janet R Kornegay; Peter Schlag; Sean Boyle; Catherine Hankins; Sylvie Vézina; Pierre Coté; John Macleod; Hélène Voyer; Pierre Forest; Sharon Walmsley; Eduardo Franco Journal: J Clin Microbiol Date: 2006-06 Impact factor: 5.948
Authors: Mark Schiffman; Nicolas Wentzensen; Sholom Wacholder; Walter Kinney; Julia C Gage; Philip E Castle Journal: J Natl Cancer Inst Date: 2011-01-31 Impact factor: 13.506
Authors: M García-Carrasco; C Mendoza-Pinto; P Munguía-Realpozo; A Rodríguez-Gallegos; V Vallejo-Ruiz; M Muñoz-Guarneros; S Méndez-Martínez; P Soto-Santillán; E Pezzat-Said; J Reyes-Leyva; A López-Colombo; A Ruiz-Argüelles; R Cervera Journal: Lupus Date: 2014-11-18 Impact factor: 2.911
Authors: Abigail Norris Turner; Patricia Carr Reese; Karen S Fields; Julie Anderson; Melissa Ervin; John A Davis; Raina N Fichorova; Mysheika Williams Roberts; Mark A Klebanoff; Rebecca D Jackson Journal: Am J Obstet Gynecol Date: 2014-06-17 Impact factor: 8.661